Atlas Trials

Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study

Clinical trial NCT06714370 · COMPLETED

Trial details

NCT number
NCT06714370
Sponsor
Ono Pharmaceutical Co., Ltd.
Status
COMPLETED
Study type
OBSERVATIONAL
Primary Central Nervous System Lymphoma (PCNSL)
Start date
2025-02-03
Primary completion
2026-03-31
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.